Genmab preparing for busy 2018

Next year, Genmab expects to obtain an approval of the company’s prize asset Darzalex for first-line therapy of multiple myeloma and provide the first data in solid tumors during the summer. Moreover, the company’s pipeline is in for a busy year, when the number of clinical candidates will double from two to four and a potentially pivotal study of the leading candidate will be initiated.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Teva lancerer billig Viagra-kopi i USA

Israelske Teva har lanceret den første generiske version af potenspillen Viagra på det amerikanske marked. Prisen kan for visse patienter være et rundt nul.

Latest Top picks in English

Related articles